Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Netakimab (DHH28805)

Host species:Humanized
Isotype:IgG1-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHH28805

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q16552

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

AG1-25, CAS: 1796570-08-5

Clone ID

Netakimab

Data Image
  • Bioactivity
    Detects Human IL17A in indirect ELISAs.
  • SDS-PAGE
    SDS PAGE for Netakimab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis, PMID: 33977094

Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study, PMID: 34237556

Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis, PMID: 33768576

Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials, PMID: 33432451

Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial, PMID: 34060012

Emerging systemic drugs in the treatment of plaque psoriasis, PMID: 32192366

IL-17 inhibition in axial spondyloarthritis: current and future perspectives, PMID: 30957574

Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19), PMID: 34346869

Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules, PMID: 34239295

Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults, PMID: 31025924

State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis, PMID: 31212119

Datasheet

Document Download

Research Grade Netakimab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Netakimab [DHH28805]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only